Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	The University of Sheffield
Country	United Kingdom
Start Date	Jan 25, 2021
End Date	Jul 14, 2021
Duration	170 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133568`

Grant Description

To appraise the clinical and cost effectiveness of osimertinib within its marketing authorisation for adjuvant treatment of non-small-cell lung cancer.